These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 19047481)

  • 1. Discovery and characterization of novel allosteric potentiators of M1 muscarinic receptors reveals multiple modes of activity.
    Marlo JE; Niswender CM; Days EL; Bridges TM; Xiang Y; Rodriguez AL; Shirey JK; Brady AE; Nalywajko T; Luo Q; Austin CA; Williams MB; Kim K; Williams R; Orton D; Brown HA; Lindsley CW; Weaver CD; Conn PJ
    Mol Pharmacol; 2009 Mar; 75(3):577-88. PubMed ID: 19047481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Probing the binding site of novel selective positive allosteric modulators at the M
    Khajehali E; Valant C; Jörg M; Tobin AB; Conn PJ; Lindsley CW; Sexton PM; Scammells PJ; Christopoulos A
    Biochem Pharmacol; 2018 Aug; 154():243-254. PubMed ID: 29777683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence for Classical Cholinergic Toxicity Associated with Selective Activation of M1 Muscarinic Receptors.
    Alt A; Pendri A; Bertekap RL; Li G; Benitex Y; Nophsker M; Rockwell KL; Burford NT; Sum CS; Chen J; Herbst JJ; Ferrante M; Hendricson A; Cvijic ME; Westphal RS; O'Connell J; Banks M; Zhang L; Gentles RG; Jenkins S; Loy J; Macor JE
    J Pharmacol Exp Ther; 2016 Feb; 356(2):293-304. PubMed ID: 26582730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological characterization of LY593093, an M1 muscarinic acetylcholine receptor-selective partial orthosteric agonist.
    Watt ML; Schober DA; Hitchcock S; Liu B; Chesterfield AK; McKinzie D; Felder CC
    J Pharmacol Exp Ther; 2011 Aug; 338(2):622-32. PubMed ID: 21558436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential regulation of muscarinic M1 receptors by orthosteric and allosteric ligands.
    Davis CN; Bradley SR; Schiffer HH; Friberg M; Koch K; Tolf BR; Bonhaus DW; Lameh J
    BMC Pharmacol; 2009 Dec; 9():14. PubMed ID: 19951444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Orthosteric and allosteric modes of interaction of novel selective agonists of the M1 muscarinic acetylcholine receptor.
    Avlani VA; Langmead CJ; Guida E; Wood MD; Tehan BG; Herdon HJ; Watson JM; Sexton PM; Christopoulos A
    Mol Pharmacol; 2010 Jul; 78(1):94-104. PubMed ID: 20413650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemical modification of the M(1) agonist VU0364572 reveals molecular switches in pharmacology and a bitopic binding mode.
    Digby GJ; Utley TJ; Lamsal A; Sevel C; Sheffler DJ; Lebois EP; Bridges TM; Wood MR; Niswender CM; Lindsley CW; Conn PJ
    ACS Chem Neurosci; 2012 Dec; 3(12):1025-36. PubMed ID: 23259038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bitopic Binding Mode of an M
    Bradley SJ; Molloy C; Bundgaard C; Mogg AJ; Thompson KJ; Dwomoh L; Sanger HE; Crabtree MD; Brooke SM; Sexton PM; Felder CC; Christopoulos A; Broad LM; Tobin AB; Langmead CJ
    Mol Pharmacol; 2018 Jun; 93(6):645-656. PubMed ID: 29695609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats.
    Jones CK; Brady AE; Davis AA; Xiang Z; Bubser M; Tantawy MN; Kane AS; Bridges TM; Kennedy JP; Bradley SR; Peterson TE; Ansari MS; Baldwin RM; Kessler RM; Deutch AY; Lah JJ; Levey AI; Lindsley CW; Conn PJ
    J Neurosci; 2008 Oct; 28(41):10422-33. PubMed ID: 18842902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reverse engineering of the selective agonist TBPB unveils both orthosteric and allosteric modes of action at the M₁ muscarinic acetylcholine receptor.
    Keov P; Valant C; Devine SM; Lane JR; Scammells PJ; Sexton PM; Christopoulos A
    Mol Pharmacol; 2013 Sep; 84(3):425-37. PubMed ID: 23798605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of a Novel M1 Muscarinic Acetylcholine Receptor Positive Allosteric Modulator Radioligand, [3H]PT-1284.
    Smith DL; Davoren JE; Edgerton JR; Lazzaro JT; Lee CW; Neal S; Zhang L; Grimwood S
    Mol Pharmacol; 2016 Sep; 90(3):177-87. PubMed ID: 27382013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potentiation of Muscarinic M
    Okimoto R; Ino K; Ishizu K; Takamatsu H; Sakamoto K; Yuyama H; Fuji H; Someya A; Ohtake A; Ishigami T; Masuda N; Takeda M; Kajioka S; Yoshimura N
    J Pharmacol Exp Ther; 2021 Oct; 379(1):64-73. PubMed ID: 34244231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AC-260584, an orally bioavailable M(1) muscarinic receptor allosteric agonist, improves cognitive performance in an animal model.
    Bradley SR; Lameh J; Ohrmund L; Son T; Bajpai A; Nguyen D; Friberg M; Burstein ES; Spalding TA; Ott TR; Schiffer HH; Tabatabaei A; McFarland K; Davis RE; Bonhaus DW
    Neuropharmacology; 2010 Feb; 58(2):365-73. PubMed ID: 19835892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel allosteric agonists of M1 muscarinic acetylcholine receptors induce brain region-specific responses that correspond with behavioral effects in animal models.
    Digby GJ; Noetzel MJ; Bubser M; Utley TJ; Walker AG; Byun NE; Lebois EP; Xiang Z; Sheffler DJ; Cho HP; Davis AA; Nemirovsky NE; Mennenga SE; Camp BW; Bimonte-Nelson HA; Bode J; Italiano K; Morrison R; Daniels JS; Niswender CM; Olive MF; Lindsley CW; Jones CK; Conn PJ
    J Neurosci; 2012 Jun; 32(25):8532-44. PubMed ID: 22723693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pharmacologic characterization of allosteric molecules: Gq protein activation.
    Bdioui S; Verdi J; Pierre N; Trinquet E; Roux T; Kenakin T
    J Recept Signal Transduct Res; 2019 Apr; 39(2):106-113. PubMed ID: 31322035
    [No Abstract]   [Full Text] [Related]  

  • 16. Molecular mechanisms of action and in vivo validation of an M4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties.
    Leach K; Loiacono RE; Felder CC; McKinzie DL; Mogg A; Shaw DB; Sexton PM; Christopoulos A
    Neuropsychopharmacology; 2010 Mar; 35(4):855-69. PubMed ID: 19940843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and Pharmacological Evaluation of Heterocyclic Carboxamides: Positive Allosteric Modulators of the M
    Dallagnol JCC; Khajehali E; van der Westhuizen ET; Jörg M; Valant C; Gonçalves AG; Capuano B; Christopoulos A; Scammells PJ
    J Med Chem; 2018 Apr; 61(7):2875-2894. PubMed ID: 29544056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contrasting effects of allosteric and orthosteric agonists on m1 muscarinic acetylcholine receptor internalization and down-regulation.
    Thomas RL; Langmead CJ; Wood MD; Challiss RA
    J Pharmacol Exp Ther; 2009 Dec; 331(3):1086-95. PubMed ID: 19767446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The M1 muscarinic receptor allosteric agonists AC-42 and 1-[1'-(2-methylbenzyl)-1,4'-bipiperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one bind to a unique site distinct from the acetylcholine orthosteric site.
    Jacobson MA; Kreatsoulas C; Pascarella DM; O'Brien JA; Sur C
    Mol Pharmacol; 2010 Oct; 78(4):648-57. PubMed ID: 20660086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Divergence of allosteric effects of rapacuronium on binding and function of muscarinic receptors.
    Jakubík J; Randáková A; El-Fakahany EE; Dolezal V
    BMC Pharmacol; 2009 Dec; 9():15. PubMed ID: 20038295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.